SUBSCRIBE

Breaking News on Global Pharmaceutical Technology & Manufacturing

Mergers and acquisitions

Mergers and acquisitions

The pharmaceutical industry seems besieged on all sides, with declining R&D productivity, expiring patents on blockbuster products and relentless downward pricing pressure forcing companies to look closely at the bottom line. One affect of this onslaught has been an upsurge in the level of M&A activity as players within the industry consolidate to cut costs, expand research pipelines and lengthen geographic reach.

Sosei looks to $23bn peptide market with acquisition of tech firm Jitsubo

15-Dec-2014 - Sosei Group Corporation is looking to peptides to replenish its pipeline through the $70m acquisition of technology firm Jitsubo.

Sun closes in on Ranbaxy deal with CCI approval

10-Dec-2014 - The Competition Commission of India (CCI) has approved Sun Pharma’s $3.2bn acquisition of Ranbaxy.

Happy Thanksgiving for GSK with FTC approval of Novartis vaccine biz

27-Nov-2014 - Just in time for the holidays, GSK can ‘give thanks’ to the US Federal Trade Commission (FTC) which has approved the $7bn acquisition of Novartis’ vaccine business.

Johnson Matthey: APIs down but Sigma-Aldrich acq could bring opportunities

24-Nov-2014 - The acquisition of Sigma-Aldrich by Merck KGaA could provide some opportunities for Johnson Matthey, the fine chemical company says as it reports a flat first half 2014/15.

BASF sells Norway plant, focuses on pharma grade omega-3 products

24-Nov-2014 - BASF says the supply of API to GSK and other pharma customers will not be affected by the divestment of an omega-3 production plant in Norway.

Actavis to acquire Botox maker Allergan for $66bn

17-Nov-2014 - After fending off hostile takeover bids from Valeant for nearly seven months, Allergan is finally agreeing to a takeover, but with Ireland-based Actavis.

Actavis takes axe to Forest again, with New York jobs to go

23-Oct-2014 - Almost 100 jobs at a commercial packaging facility in New York are set to go as part of Actavis’s continued integration of Forest Laboratories.

Strides Arcolab to leverage API business in Shasun acquisition

01-Oct-2014 - The acquisition of Shasun Pharmaceuticals will add API production and contracting services to Strides Arcolab, and according to Shasun’s CEO no jobs will be lost.

Acorda gains pulmonary drug delivery tech in $525 Civitas deal

25-Sep-2014 - Acorda has gained a pulmonary delivery technology and a GMP manufacturing site in Massachusetts along with a Parkinson’s disease candidate in its $525m (€410m) acquisition of Civitas.

Breaking news

Merck KGaA: $17bn 'Rolls Royce' Sigma-Aldrich to keep major St Louis site

22-Sep-2014 - The $17bn (€13.2bn) acquisition of Sigma-Aldrich is “not just a milestone but a quantum leap” for Merck KGaA, the firm says.

$20m Andromeda strains Hyperion as fake data ends diabetes drug development

09-Sep-2014 - Hyperion says it is “shocked and disheartened” after discovering Phase III trial data for a type 1 diabetes candidate was manipulated by employees of recently acquired Andromeda Biotech.

INFOGRAPHIC

Is Pfizer now eyeing up Actavis three months after failed AZ bid?

28-Aug-2014 - Pfizer is rumoured to be eyeing up Actavis three months after failing to woo AstraZeneca in a $120bn megamerger, but what would such a deal bring to the Pharma Giant?...

Catalent contract secure as Roche buys InterMune for $8.3bn

25-Aug-2014 - Roche has bought InterMune for $8.3bn (€6.3bn) and says it will continue contracts with Catalent and two API suppliers for the manufacture of its lead product Esbriet (pirfenidone).

Actavis welcomes AZ in boosting its LAMA/LABA

06-Aug-2014 - Actavis says it is excited to partner with AstraZeneca over its long-acting muscarinic antagonist/beta-agonist (LAMA/LABA) fixed dose combination respiratory drug following the latter’s acquisition of Almirall.

AstraZeneca coughs up $875m for Almirall to support asthma/COPD pipeline

04-Aug-2014 - AstraZeneca has bolstered its respiratory portfolio and added new bronchodilator technologies through the $875m (€650m) acquisition of Almirall.

Anti-addiction film resilient to generics, says Reckitt Benckiser

29-Jul-2014 - Reckitt Benckiser’ opioid addiction drug Suboxone delivered by sublingual film has shown a 'surprising' level of resilience against generic competition, the firm says as it plans to spin-out its pharmaceutical business....

Ben Venue assets will bolster sterile injectables network, says Hikma

28-Jul-2014 - Hikma has bought defunct manufacturer Ben Venue and says it could reactivate the site in the long-term, despite the transfer of equipment across its sterile injectables network.

UPDATE

Sterile injectables M&A could indicate return to in-house production

22-Jul-2014 - Drugmakers are bringing sterile injectables capacity back in-house according to a Frost & Sullivan analyst, who says industry risk aversion is the key driver.

Allergan further fends off Valeant with 1,500 job cuts, M&A projections

22-Jul-2014 - Botox maker Allergan announced sales and earnings per share growth above the high end of its expectations, but it will cut 1,500 jobs, or about 13% of its workforce as...

Actavis cuts down Forest as $28bn acquisition closes

10-Jul-2014 - Actavis says it is closing facilities in St. Louis, Missouri affecting 190 jobs a week after completing the $28bn (€21bn) acquisition of Forest Laboratories.

M+W sells automation biz to ATS for $350m

08-Jul-2014 - M+W says a lack of synergies with its engineering and construction business drove the decision to sell its automation divison to ATS for €255m ($348m).

Teva's 70+ manufacturing sites could be halved in efficiency drive

12-Jun-2014 - Teva could halve its manufacturing network as part of its $2bn-a-year efficiency programme says CFO Eyal Desheh, with most cuts hitting its core generics business.

Merck's $3.85bn HCV acq focused on 'valuable' nucleotide pipeline

10-Jun-2014 - Merck & Co. says the $3.85bn (€2.8bn) acquisition of Idenix will springboard its oral hepatitis C programme but according to an analyst is unlikely to threaten Gilead’s $1,000 pill Sovaldi.

AstraZeneca bid Pfizzles out as deadline passes

27-May-2014 - Pfizer has confirmed it has dropped a £69bn ($118bn) bid to buy fellow pharma giant AstraZeneca following yesterday’s acquisition deadline.

Bayer buys Merck & Co.'s OTC business for $14.2bn

06-May-2014 - Bayer says it will become the OTC leader in North America having acquired Merck & Co.’s consumer health business for $14.2bn (€10.2bn), in the latest shift in Big Pharma assets....

Key Industry Events

 

Access all events listing

Our events, Events from partners...

Products